From the Journals

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

Share

Upadacitinib demonstrates greater efficacy in reducing pain in rheumatoid arthritis (RA) than adalimumab or placebo, as revealed by post hoc analyses of phase III trials. In the SELECT-COMPARE trial, patients with RA receiving upadacitinib experienced significant pain reduction, maintaining improvements over 26 weeks. Similarly, in the SELECT-PsA 1 trial, results indicated comparable pain improvements in psoriatic arthritis (PsA), with upadacitinib showing superior efficacy over placebo. These findings highlight the drug's effectiveness beyond just inflammation control.

Original Source(s)

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

  • by Kathryn Wighton

  • February 25, 2026

  • 4 min

Related Content

Selective JAK Inhibition in RA vs PV

Tofacitinib induced remission of rheumatoid arthritis but spared JAK2-driven polycythemia vera in a single case report.

Sleep Disorders Linked to Higher RA Prevalence

Results suggest sleep-related inflammation may play a role in RA, though causality remains unclear.

What's Really Driving Arthritis Pain?

A narrative review suggests pain in rheumatoid arthritis and osteoarthritis extends beyond nociceptive mechanisms.